Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
1:25 - 100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Zeta Corporation |
Cu-18 |
1 ml |
Concentrate |
CE/IVD |
Z2141ML |
-
|
Host |
Mouse |
Klon |
Cu-18 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Zeta Corporation |
Cu-18 |
7 ml |
Ready-to-use |
CE/IVD |
Z2141MP |
-
|
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
1:25 - 100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Zeta Corporation |
Cu-18 |
0.5 ml |
Concentrate |
CE/IVD |
Z2141MS |
-
|
Host |
Mouse |
Klon |
Cu-18 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast carcinoma, fallopian tube, or skin. |
Verdünnung |
1:25 - 100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide |
Lokalisation |
Cytoplasm |
BCA-225
|
Zeta Corporation |
Cu-18 |
0.1 ml |
Concentrate |
CE/IVD |
Z2141MT |
-
|
Host |
Mouse |
Klon |
124.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Zeta Corporation |
124.0 |
1.0 ml |
Concentrate |
CE/IVD |
Z2022ML |
-
|
Host |
Mouse |
Klon |
124.0 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Zeta Corporation |
124.0 |
7 ml |
Ready-to-use |
CE/IVD |
Z2022MP |
-
|
Host |
Mouse |
Klon |
124.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Zeta Corporation |
124.0 |
0.5 ml |
Concentrate |
CE/IVD |
Z2022MS |
-
|
Host |
Mouse |
Klon |
124.0 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptide, aa 41-54 (GAAPAPGIFSSQPG-Cys) of human bcl-2 protein |
Lokalisation |
Cytoplasm |
BCL-2
|
Zeta Corporation |
124.0 |
0.1 ml |
Concentrate |
CE/IVD |
Z2022MT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM22 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsi lor diffuse large B-cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BCL-6 protein fragment (aa256-389) (exact sequence is proprietary) |
Lokalisation |
Nucleus |
BCL-6
|
Zeta Corporation |
ZM22 |
1.0 ml |
Concentrate |
CE/IVD |
Z2343ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM22 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsi lor diffuse large B-cell lymphoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BCL-6 protein fragment (aa256-389) (exact sequence is proprietary) |
Lokalisation |
Nucleus |
BCL-6
|
Zeta Corporation |
ZM22 |
7 ml |
Ready-to-use |
CE/IVD |
Z2343MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM22 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsi lor diffuse large B-cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BCL-6 protein fragment (aa256-389) (exact sequence is proprietary) |
Lokalisation |
Nucleus |
BCL-6
|
Zeta Corporation |
ZM22 |
0.5 ml |
Concentrate |
CE/IVD |
Z2343MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM22 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsi lor diffuse large B-cell lymphoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human BCL-6 protein fragment (aa256-389) (exact sequence is proprietary) |
Lokalisation |
Nucleus |
BCL-6
|
Zeta Corporation |
ZM22 |
0.1 ml |
Concentrate |
CE/IVD |
Z2343MT |
-
|
Host |
Mouse |
Klon |
100 |
Format |
Purified |
Methode |
F, WB, P, IP, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:20 - 1:40 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide, amino acids 41-54 of the Bcl-2 protein |
BCL2
|
Zytomed Systems GmbH |
100 |
100 µg |
Purified |
RUO |
602-0045 |
-
|
Host |
Mouse |
Klon |
124 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
124 |
1 ml |
Concentrate |
CE/IVD |
MOB005 |
-
|
Host |
Mouse |
Klon |
124 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
124 |
0.1 ml |
Concentrate |
CE/IVD |
MOB005-01 |
-
|
Host |
Mouse |
Klon |
124 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
124 |
0.5 ml |
Concentrate |
CE/IVD |
MOB005-05 |
-
|
Host |
Mouse |
Klon |
100/D5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
100/D5 |
1 ml |
Concentrate |
CE/IVD |
MOB130 |
-
|
Host |
Mouse |
Klon |
100/D5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
100/D5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB130-01 |
-
|
Host |
Mouse |
Klon |
100/D5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
100/D5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB130-05 |
-
|
Host |
Mouse |
Klon |
124 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Lokalisation |
Cell Membrane |
BCL2
|
Diagnostic Biosystems |
124 |
6 ml |
Ready-to-use |
CE/IVD |
PDM016 |
-
|
Host |
Rabbit |
Klon |
SP155 |
Format |
Concentrate |
Reaktivität |
MS, RT |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Human tonsil, B-cell lymphoma, HK lymphoma and follicular lymphoma tissues. |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide within Human Bcl6 aa 400-500 (C terminal) |
Lokalisation |
Nucleus |
BCL6
|
Zytomed Systems GmbH |
SP155 |
0.5 ml |
Concentrate |
RUO |
502-4552 |
-
|
Host |
Rabbit |
Klon |
SP155 |
Format |
Concentrate |
Reaktivität |
MS, RT |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Human tonsil, B-cell lymphoma, HK lymphoma and follicular lymphoma tissues. |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide within Human Bcl6 aa 400-500 (C terminal) |
Lokalisation |
Nucleus |
BCL6
|
Zytomed Systems GmbH |
SP155 |
1 ml |
Concentrate |
RUO |
502-4554 |
-
|
Host |
Mouse |
Klon |
PG-B6 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Nucleus |
BCL6
|
Diagnostic Biosystems |
PG-B6 |
1 ml |
Concentrate |
CE/IVD |
MOB587 |
-
|
Host |
Mouse |
Klon |
PG-B6 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Nucleus |
BCL6
|
Diagnostic Biosystems |
PG-B6 |
0.1 ml |
Concentrate |
CE/IVD |
MOB587-01 |
-
|
Host |
Mouse |
Klon |
PG-B6 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Nucleus |
BCL6
|
Diagnostic Biosystems |
PG-B6 |
0.5 ml |
Concentrate |
CE/IVD |
MOB587-05 |
-
|
Host |
Mouse |
Klon |
PG-B6 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Nucleus |
BCL6
|
Diagnostic Biosystems |
PG-B6 |
6 ml |
Ready-to-use |
CE/IVD |
PDM587 |
-
|
Host |
Mouse |
Klon |
151 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
BCL10
|
Diagnostic Biosystems |
151 |
1 ml |
Concentrate |
CE/IVD |
MOB442 |
-
|
Host |
Mouse |
Klon |
151 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
BCL10
|
Diagnostic Biosystems |
151 |
0.1 ml |
Concentrate |
CE/IVD |
MOB442-01 |
-
|
Host |
Mouse |
Klon |
151 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
BCL10
|
Diagnostic Biosystems |
151 |
0.5 ml |
Concentrate |
CE/IVD |
MOB442-05 |
-
|
Host |
Mouse |
Klon |
151 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
BCL10
|
Diagnostic Biosystems |
151 |
6 ml |
Ready-to-use |
CE/IVD |
PDM442 |
-
|
Host |
Mouse |
Klon |
C-10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Endometrial stromal sarcoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptideagainst amino acid 1-300 mapping at the N-terminus of BCOR of human origin |
Lokalisation |
Nucleus |
BCOR
|
Zeta Corporation |
C-10 |
1 ml |
Concentrate |
CE/IVD |
Z2334ML |
-
|
Host |
Mouse |
Klon |
C-10 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Endometrial stromal sarcoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptideagainst amino acid 1-300 mapping at the N-terminus of BCOR of human origin |
Lokalisation |
Nucleus |
BCOR
|
Zeta Corporation |
C-10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2334MP |
-
|
Host |
Mouse |
Klon |
C-10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Endometrial stromal sarcoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptideagainst amino acid 1-300 mapping at the N-terminus of BCOR of human origin |
Lokalisation |
Nucleus |
BCOR
|
Zeta Corporation |
C-10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2334MS |
-
|
Host |
Mouse |
Klon |
C-10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Endometrial stromal sarcoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
A synthetic peptideagainst amino acid 1-300 mapping at the N-terminus of BCOR of human origin |
Lokalisation |
Nucleus |
BCOR
|
Zeta Corporation |
C-10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2334MT |
-
|
Host |
Mouse |
Klon |
B 31.15 |
Format |
Purified |
Methode |
F, IF |
Isotyp |
Mouse IgG1 |
Verdünnung |
Native beta-Endorphin |
beta-Endorphin
|
Zytomed Systems GmbH |
B 31.15 |
200 µg |
Purified |
RUO |
602-0067 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Placenta |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
beta-HCG (Human Chorionic Gonadotropin)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR030 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 - 1:500 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
beta-HCG (Human Chorionic Gonadotropin)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP007 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 - 1:500 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
beta-HCG (Human Chorionic Gonadotropin)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP007-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 - 1:500 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
beta-HCG (Human Chorionic Gonadotropin)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP007-05 |
-
|
Host |
Rabbit |
Klon |
SP92 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to C-terminus of human BOB-1 protein |
Lokalisation |
Nucleus |
BOB.1
|
Zytomed Systems GmbH |
SP92 |
0.5 ml |
Concentrate |
RUO |
502-3922 |
-
|
Host |
Rabbit |
Klon |
SP92 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to C-terminus of human BOB-1 protein |
Lokalisation |
Nucleus |
BOB.1
|
Zytomed Systems GmbH |
SP92 |
1 ml |
Concentrate |
RUO |
502-3924 |
-
|
Host |
Rabbit |
Klon |
SP92 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide within Human BOB1 aa 200 to the C-terminus (C terminal) |
Lokalisation |
Nuclear |
BOB.1
|
Diagnostic Biosystems |
SP92 |
1 ml |
Concentrate |
CE/IVD |
RMAB110 |
-
|
Host |
Rabbit |
Klon |
SP92 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide within Human BOB1 aa 200 to the C-terminus (C terminal) |
Lokalisation |
Nuclear |
BOB.1
|
Diagnostic Biosystems |
SP92 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB110-01 |
-
|
Host |
Rabbit |
Klon |
SP92 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide within Human BOB1 aa 200 to the C-terminus (C terminal) |
Lokalisation |
Nuclear |
BOB.1
|
Diagnostic Biosystems |
SP92 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB110-05 |
-
|
Host |
Rabbit |
Klon |
SP92 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide within Human BOB1 aa 200 to the C-terminus (C terminal) |
Lokalisation |
Nuclear |
BOB.1
|
Diagnostic Biosystems |
SP92 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD110 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM74 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human BOB1 (POU2AF1) protein fragment (around aa 148-255) |
Lokalisation |
Cytoplasm and Nucleus |
BOB.1
|
Zeta Corporation |
ZM74 |
1 ml |
Concentrate |
CE/IVD |
Z2384ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM74 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human BOB1 (POU2AF1) protein fragment (around aa 148-255) |
Lokalisation |
Cytoplasm and Nucleus |
BOB.1
|
Zeta Corporation |
ZM74 |
7 ml |
Ready-to-use |
CE/IVD |
Z2384MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM74 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human BOB1 (POU2AF1) protein fragment (around aa 148-255) |
Lokalisation |
Cytoplasm and Nucleus |
BOB.1
|
Zeta Corporation |
ZM74 |
0.5 ml |
Concentrate |
CE/IVD |
Z2384MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM74 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human BOB1 (POU2AF1) protein fragment (around aa 148-255) |
Lokalisation |
Cytoplasm and Nucleus |
BOB.1
|
Zeta Corporation |
ZM74 |
0.1 ml |
Concentrate |
CE/IVD |
Z2384MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from C-terminus of human Bob1. |
BOB1 (OBF-1)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
502-16672 |
-
|